Finlay Vaccines Institute (IFV) Director Vicente Verez said on Twitter that he held a meeting with representatives of Iran’s Pasteur Institute, with which a collaboration agreement has been reached and signed since January. In addition, Verez met with the Iranian Health Minister, with whom he discussed scientific and technological collaboration in the field of biotechnology, especially vaccines,’ the IFV director tweeted.
As part of cooperation agreements reached by the two nations, the Cuban Covid-19 vaccine candidate, Soberana 02, developed by the IFV, completed its phase III of clinical trials in Iran at the beginning of 2021.
At the time, Organization for Food and Medicine Spokesman Kianush Yahanpur asserted that once the final results of the candidate’s effectiveness were confirmed in Iran, mass production would begin in the country.
Likewise, the IFV explained that the Iran’s Regulatory Authority granted the emergency use permit based on the recognition of the results of the product’s pharmaceutical development, the evidence of safety and immunogenicity proved in phases I/II of clinical trials conducted in Cuba.